Article
Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
JAMA network open - 1 Dec 2020
Song Jiangdian, Wang Lu, Ng Nathan Norton, Zhao Mingfang, Shi Jingyun, Wu Ning, Li Weimin, Liu Zaiyi, Yeom Kristen W, Tian Jie
Abstract excerpt
Importance: An end-to-end efficacy evaluation approach for identifying progression risk after epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy in patients with stage IV EGFR variant-positive non-small cell lung cancer (NSCLC) is lacking. Objective: To propose a clinically applicable large-scale bidirectional generative adversarial network for predicting the efficacy of EGFR-TKI...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.